ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

IKA Ilika Plc

30.50
0.00 (0.00%)
19 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ilika Plc LSE:IKA London Ordinary Share GB00B608Z994 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 30.50 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
30.00 31.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 702k -7.3M -0.0459 -6.64 48.49M
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 30.50 GBX

Ilika (IKA) Latest News

Ilika (IKA) Discussions and Chat

Ilika Forums and Chat

Date Time Title Posts
19/3/202406:58ILIKA - Multiple Material Opportunities!5,226
12/7/202319:38Ilika - First thread636
30/3/202219:47Ilika (IKA) One to Watch on Monday 28
04/2/202014:16Ilika1
03/3/201819:24Ilika plc (AIM: IKA)29

Add a New Thread

Ilika (IKA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-18 16:35:2130.005,2861,585.80O
2024-03-18 16:09:4730.005,0001,500.00O
2024-03-18 16:08:0531.00500155.00O
2024-03-18 16:08:0530.0010030.00O
2024-03-18 16:08:0531.0013742.47O

Ilika (IKA) Top Chat Posts

Top Posts
Posted at 18/3/2024 08:20 by Ilika Daily Update
Ilika Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker IKA. The last closing price for Ilika was 30.50p.
Ilika currently has 158,975,667 shares in issue. The market capitalisation of Ilika is £48,487,578.
Ilika has a price to earnings ratio (PE ratio) of -6.64.
This morning IKA shares opened at -
Posted at 08/2/2024 13:14 by robertspc1
Sondrell rocketing today on mail article linking them with Neuralink. Just imagine what could happen here if IKA tech gets real interest from the big boys. Yes I know it's risky but that's just my opinion
Posted at 16/1/2024 10:03 by robertspc1
Interesting to read about new Dyson CEO. He will be well aware of IKA from his time at JLR and the Faraday institute. Dyson could be a possible acquirer in the future. Has the resources to bring real scale to IKA technology. I'm still adding
Posted at 09/1/2024 10:56 by officerdigby
Thing about QS Battery test at VW is that was ONE battery, albeit 24 layer pouch.And achieved after circa $300m VW investment in the business.Plus qualifying statements from CEO.Point being VW staff have a lot tied up with QS appearing to be a success.. and not a waste of $$$$.I'm interested in what people mean when they say IKA is better tech than QS. Where is the data plz. I've seen QS data presentation previously and now we an important lifetime milestone from them.Where is IKA cell dataTIA!
Posted at 06/12/2023 14:42 by rogk
Bought a few just in case I'm wrong and share price goes crazy valuation re Quantumscape
Posted at 09/11/2023 16:25 by robertspc1
I pretty much agree with what you say. But and it is a big but, does the share price reflect all the past disappointment rather than the potential especially for Goliath. If their technology gets proven out then a big OEM will come knocking at a much higher price. Equally they could screw thongs up as they so nearly did with Stereax
Posted at 21/9/2023 07:58 by jimmyann
Well said Kenjen1. Rogk who has no shares in the company has no idea (look at his past comments) about Ilika. He is here just to pull down the share price. He supposedly asked a complicated question that didn't get answered.
Rogk is just full of garbage.
Posted at 04/8/2023 10:43 by shstt1
Lol, this twerp has been here yrs trying to damage the share price for IKA and therefore validate his terrible trading decisions here of the past. He used to chop and change gettin it wrong every time and having to delete his prior posts. I know you have lost a lot here Rogk or at least what you consider a lot, and it hurts you so much you are bitter and resent the company making progress as you will never profit from it. You are old and have nothing else to do, a sad life for sure. You have made your decision now to stay away from shares but cannot let it go you sad old git spending almost your entire life on here. Someone else said it - you are a saddo
I have made good money trading this, currently long from lower and I have tried giving you advice but you just can’t get it. If the market for these super tiny batteries is as big as IKA reckon, I think at this, cirtec will test the mkt and if they think they can make a mint, will swallow IKA up a few yrs down the line
Anyway, it’s not the tiny tech that interests me, there aren’t many companies you can invest in that have a solid state battery. The odds are stacked (no pun intended) but the reward is great.
Posted at 28/7/2023 06:42 by kenjen1
So where are we at then?

Stereax manufacturing agreement with cirtec must be close. The company said on investor day it was a couple of weeks away from concluding. That’s was a couple of weeks ago.

Quantum scape gave a good technical update yesterday, we could do with one of those on Goliath. QS progressing well and share price was up 25% at one point yesterday. $4b market cap that lot, if only!

Things could be about to get interesting here. Share price looking solid at these levels, ready for next leg up?
Posted at 20/2/2023 04:29 by malnu
hxxps://www.ii.co.uk/shares/ilika/LSE:IKA)is the more risky of the five companies. It had a period when it was an investor favourite, but the share price has slumped. The share price has fallen by more than three-fifths over the past year. Yet, Ilika is in a much better position than it was in early 2021 when the share price peaked.
The Stereax M300 miniature battery should be launched by the summer after some delays last year. A manufacturing licence deal with Cirtec Medical will enable a significant boost in production for Stereax. Machinery will be transferred to Cirtec Medical’s factory in Massachusetts as part of the tech transfer deal. There are initial orders from 18 medical companies and there is plenty of scope for increasing production as required.

This is not an exclusive deal and similar deals can be made around the world. Ilika continues to own the intellectual property and it can put more resources into developing the customer base, as well as further investment in the technology.
The larger Goliath battery is on the way to reaching parity with equivalent lithium-ion batteries. It is designed to be cost-effective and recyclable. Ilika has been awarded a UK government grant of £2.8 million for taking a leading role on a 24-month Faraday Battery Challenge in collaboration with BMW and Williams. This will further the development of the Goliath battery for automotive use.
Net cash was £17.8 million at the end of October 2022. The cash should last well into 2024, but there will be a requirement for more cash as Ilika approaches breakeven. By that time there sh
ould be positive news concerning demand for Stereax batteries from medical device companies. The potential for Stereax more than underpins the share price, leaving no value attributed to Goliath. Take a long-term view of this investment.
Posted at 14/12/2021 08:52 by tp5588
Posted on another site. Credit to original poster:

"Thoughts on Investor Day and Site Visit

The company has changed a lot since my last site visit (pre-Covid) and is clearly gearing up for commercialisation of their world beating intellectual property. Overall, I was very impressed with progress.

Ilika was founded on the back of ground breaking scientific research headed by Prof. Brian Hayden. He and his team have taken the science forward through advanced engineering (Tool 1 and Tool 2 were made bespoke to Ilika’s designs for example) towards commercial reality. My top take-away was that the Ilika’s management are now also adding focus and resources towards commerciality.

Most of the traffic on bulletin boards about Ilika seems to be focussed on Goliath (batteries for EV’s). Whilst there was a very full update on Goliath progress (and a tour of the new Goliath Research and Development laboratories), which is going very well (the analysts at Liberum and Berenberg both agreed that none of the big name Goliath competitors were ahead of Ilika in terms of that technology, although they are vastly higher market valuations), I will concentrate this write up on Stereax as it will be the driver of nearer term sales revenue and seems to be less well understood. Bear in mind Ilika are in many ways creating the market through the imminent availability of Stereax batteries in quantities which will allow incorporation in commercial products.

The new(ish) VP of Sales and Marketing, John Tinson was clearly out of the highest of top drawers. It was clear that Ilika are determined to nurture their client base (recall ~27 med tech device makers and 11 Internet of Things sensor makers have already been buying Ilika’s Stereax batteries for evaluation, re-certification and research and development purposes). Through his presentation and in Q&A, it was quite obvious that he understood in great detail Stereax’s market segmentation and the price inelastic nature of demand from Med Tech in particular. Tinson made clear that given the limited ability for Ilika to supply in the short term (FAB1 will be able to produce ~£13 mio worth of batteries per annum) that Ilika will be exploiting their understanding of the market for Ilika’s commercial gain.

Ilika also hired another Sales VP (who also had an impressive background and who presented very well, but whose name I can’t recall – this is my lack not his; he was equally impressive as John Tinson). Through these extremely high quality hires, it is apparent that Graeme Purdy and his top management team are focussed on turning their scientific and engineering excellence into profits for the shareholders, whilst retaining a leading position in what will be a very rapidly growing market place for nano-scale batteries.

As previously advised by the company (and in line with stock exchange rules) no market sensitive information was given. No doubt some PIs foolishly bought in anticipation of the investor day and are now dumping those (tiny) holdings. Frankly, I am sure that long term shareholders would rather not have such myopic people on the share register (which is now over 15% US based according to Steve Boydell CFO).

Having said that, personally I think they will be announcing a full year ahead orderbook not long after product validation (which will happen after process validation, as confirmed by Paul Marron, who was clearly totally on top of the production process at FAB1).

They are also currently evaluating the relative merits of increasing capacity at FAB1, bringing in-house the rest of the many processes (thinning and dicing for instance) of Stereax production and FAB2 (for which there is space next door…). Recall that the cost of FAB2 was already raised in the May 2020 fund raise (which I am glad to have taken part in).

If there is an area of weakness, it was in my opinion their ham-fisted fund-raise of ~£25 mio for Goliath at a 30% discount to the prevailing market. If they needed the money (which they did; in comparison QuantumScape are making losses greater than the entire market capitalisation of Ilika in less than 3 months, every 3 months ...), they should have raised when the share price was rising above £2.75 less than 6 months earlier. This would have resulted in greater funds at lesser dilution. However, that is now in the past and the money at least has been raised and is being put to extremely efficient use.

In summary, we already knew that Brian Hayden and his team were world leaders in terms of the tech (both the chemistry and in overcoming engineering problems to turn the science into commercially viable product). The shift of focus to commerciality was definitely needed, but the quality of their hiring shows just how able to evolve this Management team are. They will need to follow this up with results next financial year in terms of Sales and scale-up plans in order to continue to show their effectiveness.

I am delighted with their approach of setting realistic guidance and delivering it (rather than making wild claims to gather attention, and then failing to deliver, which any student of the history of the battery industry will know it is littered with). The future looks extremely bright for long term Ilika shareholders imo."
Ilika share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com